The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts).
 
Carlo Resteghini
Honoraria - SUN PHARMA
 
Paolo Castelnuovo
No Relationships to Disclose
 
Piero Nicolai
No Relationships to Disclose
 
Ester Orlandi
No Relationships to Disclose
 
Paolo Bossi
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Regeneron
Consulting or Advisory Role - Angelini Pharma; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Sanofi/Regeneron; Sun Pharma
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD Oncology (Inst); Regeneron (Inst); Roche (Inst)
 
Barbara Vischioni
Honoraria - Merck
 
Alberto Schreiber
No Relationships to Disclose
 
Nicola Alessandro Iacovelli
No Relationships to Disclose
 
Paolo Battaglia
No Relationships to Disclose
 
Davide Mattavelli
No Relationships to Disclose
 
Nadia Facchinetti
Travel, Accommodations, Expenses - Helsinn Healthcare
 
Simone Gambazza
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Marco Ravanelli
No Relationships to Disclose
 
Carla Facco
No Relationships to Disclose
 
Tiziana Tartaro
No Relationships to Disclose
 
Andrea Pietro Sponghini
No Relationships to Disclose
 
Fabio Pagella
No Relationships to Disclose
 
Luigi Mariani
No Relationships to Disclose
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Doxapharma; Eisai; GlaxoSmithKline; Incyte; Ipsen; Merck Serono; MSD; Nanobiotix; Novartis; Roche; SOBI
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Serono; MSD